No apparent effect of the COVID-19 pandemic on out-of-hospital cardiac arrest incidence and outcome in Western Australia.

BACKGROUND: We examined the incidence, patient and arrest characteristics, and survival outcomes of out-of-hospital cardiac arrest (OHCA) in Western Australia (WA) in the first wave of the COVID-19 pandemic. METHODS: Adult OHCA cases attended by St John WA Emergency Medical Service (EMS) between 16th March and 17th May 2020 ('COVID-19 period') were compared with those for the same period in 2017-9. We calculated crude OHCA incidence for all OHCA cases and modelled the effect of the 'COVID-19 period' on 30-day survival for OHCA cases with EMS attempted resuscitation; comparing our results with those published for Victoria (Australia), which had a higher incidence of COVID-19. RESULTS: In WA there was no significant difference between the 2020 'COVID-19 period' (n = 423) and the same period in 2017-9 (n = 1,334) in the OHCA incidence in adults (117.9 vs 126.1 per 100,000 person-years, p = 0.23). In OHCA cases with EMS-resuscitation attempted, there was no change in bystander cardiopulmonary resuscitation rates. Despite an increase in EMS response time, neither the crude nor risk-adjusted odds ratio (aOR) for 30-day survival in 2020 was significantly different to 2017-9 (11.7% vs 9.6%; p = 0.45) (aOR = 1.19, 95% confidence interval 0.57-2.51, p = 0.65). This contrasts with a significant reduction in survival to hospital discharge reported in Victoria. CONCLUSION: In WA, with a relatively low incidence of COVID-19, OHCA incidence and survival was not significantly different during the initial wave of the COVID-19 pandemic compared to the three previous years. Our study suggests that OHCA survival may be more closely related to the incidence of COVID-19 in the community, rather than COVID-19 restrictions per se.

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.

The past decade has seen substantial progress in understanding the pathobiology, natural history, and clinical significance of idiopathic pulmonary fibrosis (IPF), culminating in the establishment of two effective medical therapies. Now seems an important time to reconsider the design and conduct of future IPF clinical trials. Building on lessons learned over the past decade, we use this perspective to lay out four key considerations for moving forward effectively and efficiently with the next generation of clinical trials in IPF. These are: development of a coordinated IPF clinical trials network; establishment of expectations for early phase proof of concept studies; adaptation of late-phase efficacy trial designs to the emergence of approved therapies, and; agreement on primary end-points for late phase clinical trials. Continued progress in the field of IPF will require creativity and collaboration on the part of all stakeholders. We believe that addressing these four considerations will encourage and enable investment in this new era of drug development in IPF, and will lead to more rapid development of effective therapies.

Open-access biorepository for idiopathic pulmonary fibrosis. The way forward.

Although widespread use of animal modeling has transformed pulmonary research, the overarching goal of biomedical research is to enhance our understanding of human physiology and pathology. Thus, we believe that future gains in understanding human lung disease will be enhanced when studying patient-derived samples becomes an integral part of the investigational process. For idiopathic pulmonary fibrosis (IPF), investigators need quality human specimens, collected in a standardized fashion, along with carefully annotated, long-term clinical and outcomes data to address current knowledge gaps. Access to human lung tissues through commercial entities or the Lung Tissue Resource Consortium, an NHLBI-funded consortium, has demonstrated the feasibility of this approach. However, these samples are not always well annotated or collected uniformly and are limited in their breadth to address future IPF research needs. Therefore, we propose leveraging ongoing and future studies in IPF to establish a biorepository that will meet current and future needs of IPF investigations. Specifically, we propose that blood, cell, and lung samples, linked to robust longitudinal clinical phenotyping generated from future industry, federally sponsored, and investigator-initiated clinical studies be prospectively and uniformly collected and stored in a biorepository and linked registry. Here we outline standardized methodologies that would allow specimens and clinical data collected from different studies to be integrated and accessible to the IPF research community for investigations that will inform future basic and translational research in IPF. Such a biorepository needs the combined efforts of all stakeholders, to be driven by projected future scientific needs and to be available to all qualified researchers. We believe this infrastructure is crucial, is feasible, and would accelerate research in IPF.